Intrexon reported $162.81M in Current Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agenus AGEN:US USD 251.43M 37.5M
Amgen AMGN:US USD 24.06B 4.74B
Anika Therapeutics ANIK:US USD 167.76M 95K
Arrowhead Research ARWR:US USD 432.39M 14.76M
AstraZeneca AZN:LN USD 20.22B 693M
Bluebird Bio BLUE:US USD 160.44M 7.02M
Bristol Myers Squibb BMY:US USD 26.8B 3.39B
Gilead Sciences GILD:US USD 13.9B 723M
GlaxoSmithKline GSK:LN GBP 20.25B 33.94B
Heron Therapeutics HRTX:US USD 223.8M 29.6M
Immunogen IMGN:US USD 330.42M 63.51M
Intrexon XON:US USD 162.81M 1.81M
Karyopharm Therapeutics KPTI:US USD 222.68M 19.77M
Ligand Pharmaceuticals LGND:US USD 220.43M 23.35M
Macrogenics MGNX:US USD 147.81M 19.82M
Mannkind MNKD:US USD 218.38M 24.9M
Novartis NOVN:VX USD 36.95B 1.19B
Peregrine Pharmaceuticals PPHM:US USD 180.64M 612K
Rigel Pharmaceuticals RIGL:US USD 110.44M 10.08M
Sangamo Biosciences SGMO:US USD 336.62M 6.5M
Thermo Fisher Scientific TMO:US USD 19.3B 1.2B
Veracyte VCYT:US USD 238.52M 3.47M
Xencor XNCR:US USD 668M 82.06M
YTE INCY:US USD 3.82B 195.27M
Ziopharm Oncology ZIOP:US USD 55.5M 5.86M